Key Points
GSK expects $1.17 EPS and $10.23B revenue on April 29, 2026
Company beat revenue estimates in three of four recent quarters
Meyka AI rates GSK with B grade reflecting solid fundamentals
Vaccine portfolio and specialty medicine drive earnings growth
GSK plc will report first-quarter earnings on April 29, 2026 after market close. Analysts expect $1.17 earnings per share and $10.23 billion in revenue. The pharmaceutical giant has beaten revenue estimates in three of its last four quarters, showing consistent operational strength. GSK trades at $54.22 with a market cap of $108.74 billion. Meyka AI rates GSK with a grade of B, reflecting solid fundamentals and sector positioning. This earnings preview examines what to expect and key metrics investors should monitor.
What Analysts Expect from GSK Earnings
Wall Street has set clear expectations for GSK’s first-quarter earnings report. Analysts project $1.17 in earnings per share and $10.23 billion in total revenue. These estimates represent important benchmarks for evaluating company performance.
EPS Estimate Analysis
The $1.17 EPS estimate sits between recent quarterly results. GSK reported $1.13 EPS in Q3 2025 and $1.23 EPS in Q2 2025. This suggests analysts expect modest earnings in the current quarter. The company has beaten EPS estimates in two of the last three quarters, demonstrating management’s ability to exceed expectations.
Revenue Estimate Context
The $10.23 billion revenue estimate aligns with GSK’s recent performance trajectory. The company generated $9.70 billion in Q3 2025 and $10.88 billion in Q2 2025. GSK has consistently exceeded revenue targets, beating estimates in three consecutive quarters. This track record suggests strong commercial execution across vaccine and specialty medicine divisions.
Historical Beat and Miss Pattern
GSK shows a strong pattern of beating revenue estimates. Over the last four quarters, the company exceeded revenue expectations in three instances. EPS results have been more mixed, with two beats and one miss. This suggests GSK’s strength lies in top-line growth rather than margin expansion.
Key Metrics and Financial Health
GSK’s financial position reflects a mature pharmaceutical company with solid cash generation and strategic focus. Understanding key metrics helps investors assess earnings quality and sustainability.
Profitability and Margins
GSK maintains a 17.5% net profit margin, indicating efficient cost management. The company’s operating margin of 24.3% demonstrates strong pricing power in vaccines and specialty medicines. Gross margins of 72.5% reflect the high-margin nature of pharmaceutical products. These metrics suggest GSK can sustain profitability even during competitive pricing pressures.
Cash Flow and Dividend Strength
Operating cash flow per share reached $4.13, while free cash flow per share stands at $3.10. GSK pays a $1.32 dividend per share annually, yielding 3.28%. The company’s payout ratio of 49% leaves room for dividend growth or reinvestment. Strong cash generation supports both shareholder returns and R&D investments.
Valuation Metrics
GSK trades at a 14.1x price-to-earnings ratio, below the healthcare sector average. The 2.47x price-to-sales ratio suggests reasonable valuation for a diversified pharma company. These multiples indicate the market prices GSK conservatively relative to growth prospects and dividend yield.
What to Watch During the Earnings Call
Investors should focus on specific business drivers and forward guidance when GSK reports results. These factors will shape stock performance and investor sentiment.
Vaccine Portfolio Performance
GSK’s vaccine division drives significant growth. Watch for updates on shingles, meningitis, and RSV vaccines. The company’s collaboration with CureVac on mRNA influenza vaccines represents future growth potential. Strong vaccine sales would validate GSK’s strategic pivot toward preventive medicine and support revenue growth.
Specialty Medicine Momentum
The specialty medicine segment includes HIV, oncology, and respiratory treatments. Management should discuss market share trends and new product uptake. GSK’s respiratory portfolio remains important given chronic disease prevalence. Positive commentary on specialty medicine would support the $1.17 EPS estimate.
R&D Progress and Pipeline Updates
GSK invests 22.9% of revenue in research and development. Investors should listen for updates on Parkinson’s disease treatments and fibrotic disease programs. Pipeline progress directly impacts long-term earnings potential. Successful clinical trial results could justify premium valuations and drive stock appreciation.
Guidance and Outlook
Management guidance for full-year earnings and revenue matters most. GSK has beaten revenue estimates consistently, so conservative guidance could disappoint. Watch for commentary on pricing, volume trends, and competitive dynamics. Forward guidance will shape investor expectations for subsequent quarters.
Meyka AI Grade and Investment Perspective
Meyka AI rates GSK with a grade of B, reflecting balanced strengths and considerations. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Grade Components and Meaning
The B grade indicates GSK is a solid healthcare investment with reliable fundamentals. The company scores well on profitability metrics, cash flow generation, and dividend sustainability. GSK’s 14.1x P/E ratio and 3.28% dividend yield appeal to income-focused investors. However, the grade reflects modest growth expectations relative to biotech peers.
Analyst Consensus and Sentiment
Current analyst ratings show 5 Hold recommendations and 4 Sell recommendations, with no Buy ratings. This mixed sentiment reflects concerns about growth limitations in mature markets. The consensus rating of 2.0 suggests neutral positioning. Investors should interpret this as “fairly valued” rather than compelling.
Technical Indicators and Price Action
GSK’s RSI of 40.6 indicates oversold conditions, potentially attractive for value investors. The stock trades 11.8% below its 52-week high of $61.70, suggesting recent weakness. Technical indicators show MACD histogram of -0.41, indicating bearish momentum. Strong earnings could reverse negative technical trends and attract technical traders.
Final Thoughts
GSK’s April 29 earnings will reveal if the company maintains its revenue beat streak while hitting the $1.17 EPS target. With strong vaccine and specialty medicine portfolios, the $10.23 billion revenue estimate looks achievable. Investors should monitor vaccine performance and forward guidance. GSK offers stable dividend income rather than growth, earning a B grade from Meyka AI. Oversold technical indicators suggest potential sharp stock movement on results, which could appeal to value investors seeking steady cash flow.
FAQs
What is the EPS estimate for GSK’s April 29 earnings?
Analysts expect GSK to report **$1.17 earnings per share** for the quarter. This estimate sits between recent quarterly results of $1.13 and $1.23, suggesting stable earnings performance. GSK has beaten EPS estimates in two of the last three quarters.
What revenue does Wall Street expect from GSK?
The consensus revenue estimate is **$10.23 billion**. GSK has beaten revenue expectations in three consecutive quarters, generating $9.70 billion and $10.88 billion in recent periods. This track record suggests the company may exceed current estimates.
How has GSK performed against earnings estimates historically?
GSK shows strong revenue beat patterns, exceeding estimates in three of four recent quarters. EPS results are more mixed with two beats and one miss. This suggests GSK’s strength lies in sales growth rather than margin expansion or cost control.
What is Meyka AI’s grade for GSK and what does it mean?
Meyka AI rates GSK with a **B grade**, indicating solid fundamentals and reliable cash flow. The grade reflects balanced profitability, dividend sustainability, and sector positioning. It suggests GSK is fairly valued rather than offering exceptional growth potential.
What should investors watch during GSK’s earnings call?
Focus on vaccine portfolio performance, specialty medicine momentum, R&D pipeline updates, and forward guidance. Watch for commentary on pricing trends, competitive dynamics, and market share. Management guidance will shape expectations for future quarters and stock performance.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)